EXMceuticals (EXM) is a producer of highly refined cannabis ingredients for the pharmaceutical, medical, nutraceutical, and cosmetic industries. The company is poised to penetrate the lucrative pharmaceutical market for CBD and other regulated cannabinoids on a B2B basis in the next 12 months.
On 25th March 2020, EXM announced that, as a result of a strategic review carried out over previous months, its sole focus going forward will be on the further establishment and expansion of its Portuguese and European operations, in particular, its existing R&D operations and the planned industrial cannabis ingredients refinery near Lisbon. Development of the company’s African agriculture operations has, as a result, now been halted.
EXM has completed the detailed planning for the fit-out of an existing industrial facility, to create a pharmaceutical-grade factory, operating at scale, certified to EU-GMP standards. First production of cannabis derived medical ingredients, including CBD, is expected around seven months following the receipt of funding for the project, with an initial refining capacity of 4,500 kg a year of pure EU-GMP end-product. The detailed factory design includes the potential for a fourfold capacity rise. EXM estimates c.US$15 million is needed to complete the refinery to the required standard and operate it for one year.
EXM has chosen Portugal as its base partly due to the highly favourable regulatory regime and location, from which it can serve both the European and North American markets. Analysts at Brightfield Group predict that the European CBD market (including e-cigarette fluids) will rise from €373 million in 2019 to €1.5 billion by 2023, with the global market expected to be worth €14.4 billion by 2025. Other analysts project far higher numbers. The global medical cannabis market size was US$16.5 billion in 2019 and is expected to reach a value of US$56.5 billion by 2025, exhibiting a CAGR of 22.8% during 2020-2025.
Our analysis shows that EXM’s business model is potentially highly profitable, with net profit margins of 35% achievable once initial production levels are achieved. Assuming equity funds are raised (at the current share price of CAD$0.22) to fund the refinery we calculate a post-money price per share of CAD$0.958, representing upside of 336%. However, our per share valuation would be vastly improved should any funds be raised via debt, up to CAD$2.50 per share assuming 100% debt. We update coverage of EXMceuticals with a stance of Conviction Buy.
Align Research is a commissioned research company founded in November 2015 in order to provide the under-served smaller company space with high quality analysis. We have an initial focus on the natural resources sector, in which we see significant opportunities given the current once in a generation bear market, however all undervalued small caps (sub £100m) are considered by our team. Align was founded by industry professionals with decades of experience in the stock markets, headed up by highly qualified individuals from both fund management and analytical backgrounds.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.